Keith William Pratz MD
Associate Professor of Medicine, Director of Leukemia, University of Pennsylvania
Join to View Full Profile
3400 Civic center BLVDPCAM South 12-155Philadelphia, PA 19104
Dr. Pratz is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2006 - 2009
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2002 - 2005
Rutgers Robert Wood Johnson Medical SchoolClass of 2002
Certifications & Licensure
PA State Medical License 2019 - 2026
MD State Medical License 2006 - 2019
MN State Medical License 2003 - 2007
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2014, 2016-2017
Clinical Trials
- Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders Start of enrollment: 2008 Feb 04
- Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2012 Jan 13
- Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Start of enrollment: 2014 May 19
Publications & Presentations
PubMed
- Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.Eunice S Wang, Harry P Erba, Amer M Zeidan, Gail J Roboz, Jessica K Altman
Blood. 2026-06-02 - A real-world analysis of the impact of azole antifungal prophylaxis on outcomes in patients with newly diagnosed acute myeloid leukemia treated with venetoclax-based t...Alexander Ambinder, Mark Levis, Xin Wang, Keith Pratz, Andrew Matthews
Leukemia Research. 2026-05-01 - Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial.James M Foran, Zhuoxin Sun, Selina M Luger, David F Claxton, Hillard M Lazarus
Blood Neoplasia. 2026-05-01
Journal Articles
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaCourtney D Dinardo, Brian A Jonas, Jacqueline S Garcia, Anthony Letai, Wan-Jen Hong, Keith W Pratz, The New England Journal of Medicine
- Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid LeukemiaBrian A Jonas, Courtney D DiNardo, Olga Frankfurt, Daniel A Pollyea, Keith Pratz, Anthony Letai, Martha Arellano, Marina Konopleva, Hagop M Kantarjian, Blood
Abstracts/Posters
- Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeKeith W. Pratz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b StudyClinically Relevant AbstractKeith W. Pratz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)Keith W. Pratz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Management of Neutropenia during Venetoclax-Based Combination Treatment in Patients with Newly Diagnosed Acute Myeloid Leukemia61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- New Therapies for Better Patient Outcomes in Acute Myeloid Leukemia: Integration of Recent Data Sets Into Clinical Practice60th American Society of Hematology Annual Meeting - 11/30/2018
Authored Content
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
Press Mentions
Keith W. Pratz, MD, on the Prognostic Value of MRD in AML Low-Intensity TreatmentJune 3rd, 2022
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/keith-pratz
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
